miRNA-5585-5p靶向调控多聚免疫球蛋白受体在乳腺癌中的表达及临床意义

Expression and significance of polymeric immunoglobulin receptor regulated by miR-5585-5p in breast cancer

目的:探讨微小RNA(microRNA,miR)-5585-5p调控多聚免疫球蛋白受体(pIgR)表达情况和pIgR在乳腺癌组织及良性乳腺肿瘤组织中的差异表达。方法:采用生物信息学方法,利用癌症基因组图谱数据库,分析miR-5585-5p对pIgR的调控作用,以及pIgR在乳腺癌组织与正常乳腺组织中的差异表达,并进行生存分析;采用荧光定量PCR技术,检测miR-5585-5p对pIgR的调控作用;采用免疫组织化学方法检测乳腺浸润性导管癌病人肿瘤组织和非癌症病人正常乳腺组织中pIgR表达情况,并分析pIgR表达与乳腺癌病人临床病理特征间关系。结果:荧光定量PCR结果显示,miR-5585-5p下调pIgR表达(P<0.01);生物信息学分析显示,pIgR在乳腺癌病人中呈低表达趋势(P<0.01);免疫组织化学结果显示,不同组织学分级、淋巴结转移数目和HER-2、ER表达病人的pIgR表达差异均有统计学意义(P<0.05~P<0.01)。结论:miR-5585-5p靶向调控pIgR表达,并与乳腺癌病人预后相关,提示其可能可作为生物标志物,帮助进行乳腺癌的分子分型、预后判断及治疗方案选择。

Objective:To investigate the expression of polymeric immunoglobulin receptor(pIgR)regulated by microRNA(miR)-5585-5p and the differential expression of pIgR in breast cancer tissue(BRCA)and non-cancer tissues(NCT).Methods:Bioinformatics method was used to analyze the regulatory effect of miR-5585-5p on pIgR,the expression of pIgR in breast cancer and its effect on survival and prognosis of patients.Fluorescence quantitative PCR was used to detect the regulatory effect of miR-5585-5p on pIgR.Immunohistochemical method was used to detect the expression of pIgR in tumor tissues of breast invasive ductal carcinoma patients and normal breast tissues of non-cancer patients,and to analyze the relationship between the expression of pIgR and the clinicopathological characteristics of patients in BRCR group.Results:miR-5585-5p down-regulated the expression of pIgR(P<0.01).Bioinformatics analysis showed that the expression of pIgR was low in breast cancer patients(P<0.01).Immunohistochemical results showed that there were significant differences in the expression of pIgR among patients with different histological grades,lymph node metastasis numbers and HER-2,ER expression(P<0.05 to P<0.01).Conclusions:miR-5585-5p targets to regulate the expression of pIgR and is associated with the prognosis of breast cancer patients,suggesting that it may be used as a biomarker to help molecular typing,prognosis judgment and treatment scheme selection of breast cancer.